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Abstract 15 
The reaction of the potential anti-cancer drug kiteplatin, cis-[PtCl2(cis-1,4-DACH)], with 16 
oligomers of single- and double-stranded DNA ranging from 2 to 12 base pairs in length was 17 
performed as a model for DNA interaction. The potential for conformational flexibility of 18 
single-stranded adducts was examined with density functional theory (DFT), and compared 19 
with data from 
1
H-NMR 1D and 2D spectroscopy. This indicates the presence of multiple 20 
conformations of an adduct with d(GpG), but only one form of the adduct with d(TGGT). 21 
The importance of a suitable theoretical model, and in particular basis set, in reproducing 22 
experimental data is demonstrated. The DFT theoretical model was extended to platinated 23 
base pair step (GG/CC), allowing a comparison to the related compounds cisplatin and 24 
oxaliplatin. Adducts of kiteplatin with larger fragments of double-stranded DNA, including 25 
tetramer, octamer, and dodecamer, were studied theoretically using hybrid QM/MM methods. 26 
Structural parameters of all the base paired models were evaluated and binding energies 27 
calculated in gas phase and in solution; these are compared across the series, and also with 28 
the related complexes cisplatin and oxaliplatin, thus revealing insights into how kiteplatin 29 
binds to DNA, and similarities and differences between this and related compounds. 30 
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Introduction 35 
Platinum complexes, such as the archetypal cisplatin (cis-[PtCl2(NH3)2]), comprise one of the 36 
most widely used classes of anticancer drugs in the world. First synthesized in the nineteenth 37 
century, interest in cisplatin was sparked in the 1960s following Rosenberg’s serendipitous 38 
discovery of cytotoxicity.
1
  Marketed as Platinol, this is now widely used as an effective first 39 
line treatment for many cancers.
2
 Despite this success, drawbacks associated with severe 40 
systemic toxicity have stimulated much interest in the development of improved platinum 41 
drugs, and in understanding the molecular mechanism that explains the biological activity of 42 
platinum compounds.
3,4
 Such complexes show antitumour activity due to the formation of 43 
cytotoxic lesions on DNA with platinum adducts, preventing replication and eventually 44 
causing cell death.
5
 45 
 46 
 47 
 
 
 
 48 
Figure 1 Structures of cisplatin (left), oxaliplatin (middle) and kiteplatin (right). 49 
 50 
Oxaliplatin is a globally used alternative to cisplatin, and is not only better tolerated in the 51 
body but also displays a different spectrum of activity,
6
 being particularly active against 52 
colorectal cancer.
7
 This drug incorporates a 1R,2R-diaminocyclohexane (DACH) carrier 53 
group that is retained on binding to DNA, and is believed to facilitate transport into cells as 54 
well as formation of different DNA adducts than found with cisplatin. The origin and specific 55 
nature of these differences has been extensively studied, primarily by NMR spectroscopy.
8,9
 56 
It is believed that oxaliplatin forms fewer crosslinks than cisplatin at equimolar 57 
concentrations as adducts are bulkier and more hydrophobic, leading to different effects in 58 
the cell.
9,10
  59 
 60 
The complex [PtCl2(cis-1,4-DACH)], dubbed kiteplatin, contains an isomeric form of the 61 
oxaliplatin diamine ligand. Early studies indicated potency greater than cisplatin or 62 
oxaliplatin against several cell lines, and the potential for a different spectrum of activity 63 
 3 
from those drugs.
11
 Recently, activity against colon cancer cells that are resistant to 64 
conventional chemotherapy has been demonstrated.
12
 Moreover, the unusual coordination 65 
geometry of kiteplatin, which contains a seven-membered chelate ring and large bite angle 66 
(ca. 97 °),
 
leads to quite different conformational behaviour of complexes with free guanines 67 
or single-stranded DNA oligomers.
13
 This feature might be correlated to the effectiveness of 68 
DNA-adducts of kiteplatin of blocking the Pol-catalyzed DNA synthesis.14,15  69 
 70 
Experimental techniques such as NMR
9
 and X-ray crystallography
16
 can shed a great deal of 71 
light into the mode of action of such drugs, especially their interaction with DNA. Of 72 
particular relevance for the current work is a recent study that used 
1
H and 
31
P 1D and 2D 73 
NMR spectroscopy to determine conformations of kiteplatin’s adducts with single-stranded 74 
DNA and their potential for interconversion.
17
 Theoretical predictions from models based on 75 
quantum mechanics (QM), molecular mechanics (MM) or a combination of these (QM/MM) 76 
are increasingly used to complement such experiments.
18
 A great many such studies have 77 
clarified and quantified various aspects of cisplatin’s biochemistry, including the kinetics and 78 
thermodynamics of aquation and binding to DNA and other biological molecules, and the 79 
distortions induced in DNA on binding.
19,20,21,22,23
 Similar studies of oxaliplatin and other 80 
alternatives have been reported, illuminating the similarities and differences between 81 
drugs.
24,25
 Density functional theory (DFT) is the method of choice in almost all such studies, 82 
offering an excellent balance between accuracy and computational time and effort required. 83 
Properly chosen DFT methods correctly describe covalent and non-covalent bonding within 84 
platinum complexes and DNA, and between these species. However, such methods are 85 
typically applicable to a few hundred atoms with current computing, effectively limiting the 86 
size of DNA fragment to just two base pairs. Molecular mechanics (MM) methods are 87 
capable of describing much larger systems, and also to rapidly explore conformational 88 
freedom as in the recent study of cisplatin-TGG adducts,
23
 but to date parameters are 89 
available only for cisplatin and oxaliplatin. 90 
 91 
Recently, we set out hybrid QM/MM approaches for study of the interaction of platinum 92 
drugs with fragments of DNA from 2 to 12 base pairs, potentially including associated 93 
counterions and explicit solvent molecules. In this approach, platinum and ligands along with 94 
coordinated bases are treated with DFT, while the remainder of the DNA, counterions and 95 
solvent are treated with much more efficient MM methods. In our first study, the ability of 96 
 4 
this approach to reproduce X-ray crystallographic and NMR structures of cisplatin with 2 and 97 
8 DNA base pairs was tested, confirming the suitability of this approach.
26
 A second study 98 
compared the binding of five drugs, including cisplatin and oxaliplatin, to octameric DNA, 99 
highlighting the importance of non-covalent as well as covalent interactions between drug 100 
and DNA and comparing the distortions induced by different drugs.
27
 In this work, we apply 101 
DFT and QM/MM methods to kiteplatin-DNA complexes, with the twin goals of testing this 102 
approach against experimental NMR data, and subsequently discovering how the 103 
coordination geometry of kiteplatin affects binding and disruption of DNA. 104 
 105 
Computational methods 106 
DFT calculations were carried out using Gaussian09,
28
 using the B97-D method
29
 along with 107 
TZVP basis set,
30
 taking advantage of the resolution of identity (RI) method. Solvated DFT 108 
calculations used the polarized continuum model (PCM) of aqueous phase.
31
 QM/MM studies 109 
used the ONIOM method,
32
 as implemented in Gaussian 09, with the high layer treated with 110 
BHandH/6-31+G**;
33
 with SDD basis set and ECP on Pt, and the low layer with the 111 
AMBER (parm96.dat) forcefield.
34
 In these calculations the QM layer includes Pt, ligand and 112 
the two coordinated guanines, while the MM layer is the remainder of the DNA fragment 113 
being studied, the sodium counterions, and any explicit water molecules present. For 114 
calculations on the QM layer the N9—C1' bond was broken and C1' replaced by hydrogen 115 
link atoms: see ref. 26 for further details. Optimisations were carried out using the GEDIIS 116 
algorithm,
35
 and in some cases micro-iterations were also used. Relaxed potential energy 117 
scans were performed by freezing the torsion angle associated with 4 atoms centred on Pt-N7 118 
bonds and relaxing all other coordinates, then varying the frozen torsion in steps of ±10. 119 
This approach was previously validated against experimental data for complexes of various 120 
drugs with DNA oligomers.
27
 In particular, comparison against NMR data for cisplatin 121 
complexes show that results do not depend strongly on parameters for the metal, since these 122 
cancel in the ONIOM expression. Calculation of binding energies in QM/MM models 123 
employed the polarizable continuum model (PCM) approach
36
 after removal of explicit 124 
waters, using the cavity of the full system for all necessary calculations. Analysis of the 125 
resulting DNA structures was performed using X3DNA,
37
 and exposed surface area 126 
calculated using MOLVOL.
38
 127 
 128 
 129 
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 130 
 131 
Results and Discussion 132 
Adducts with single stranded DNA 133 
The anticancer activity of cisplatin is triggered by the formation of adducts involving two 134 
adjacent guanines of DNA coordinated to the metal by their N7 atoms. The two cross-linked 135 
guanines adopt primarily a Head-to-Head (HH) arrangement with both G’s having their H8 136 
atoms on the same side of the platinum coordination plane. In contrast, the G bases adopt a 137 
Head-to-Tail (HT) arrangement in interstrand cross-links, which could also contribute to the 138 
anticancer activity.
39
 Fast rotation, on the NMR time scale, about the Pt-N7 bonds in Pt(G)2 139 
adducts with untethered Gs greatly diminishes the informative potential of the NMR 140 
techniques when two ammines (such as in cisplatin) or a primary diamine are coordinated to 141 
platinum. The very large bite angle of cis-1,4-DACH in kiteplatin was exploited to diminish 142 
the dynamic motion and the interconversion between possible conformers. This was 143 
confirmed by the results obtained with the (cis-1,4-DACH)Pt(5'-GMP)2 adduct, for which, at 144 
low temperature, three possible conformers (one HH and two HTs) were observed by 
1
H-145 
NMR.
13 
Recent work showed that some or all of the four (2 HH and 2 HT; Scheme 1) 146 
possible conformers in adducts with single-stranded d(GpG) interconvert with a rate which is 147 
fast on the NMR time scale. Using a combination of variable temperature 
1
H- and 
31
P- and 148 
2D-NMR spectroscopy, the dominant conformation was identified as HH1, with significant 149 
amounts of HT1 at close to the physiological temperature (40 °C). Hence the cis-1,4-DACH 150 
ligand does not strongly influence the relative stability of conformers, but rather their 151 
interconversion rate due to the impeded rotation of the guanine bases with respect to the Pt-152 
N7 bonds. This finding could be one of the reasons that may explain the difference in 153 
biological activity of kiteplatin as compared to that of cisplatin and oxaliplatin. 154 
  155 
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 158 
Scheme 1. Four possible conformers of adducts containing the Pt(dGpG) cross-link. The 159 
arrows represent the G bases while the phosphodiester backbone is represented by a curved 160 
dashed line linking the two arrows. Interconversion between conformers is possible via 161 
rotation about the Pt-G bonds. HT2 and HT1 differ, respectively, in the  and  handedness 162 
of GpG relative to the coordination plane. HH2 and HH1 differ, respectively, for the south or 163 
north orientation of the arrows representing the guanines, having placed 5'-G on the left- and 164 
3'-G on the right-hand side. In the HH1 arrangement both Gs maintain the B-DNA anti 165 
conformation. Canting handedness is defined by two straight lines, one connecting the N7 166 
atoms of the two coordinated guanines and the other overlapping the arrow representing a 167 
given guanine. 168 
 169 
In order to examine the conformational preferences in kiteplatin-d(GpG) adduct, we turn to 170 
theoretical methods. We previously reported the use of MM methods to explore the 171 
conformational space of this adduct,
17
 which located 54 conformations in total, with between 172 
7 and 21 structures belonging to each family of conformers indicated in Scheme 1. Here, we 173 
employ DFT methods to obtain more reliable predictions, and also to examine the origin of 174 
 7 
observed preferences in more detail. We first carried out geometry optimisation on all 54 175 
complexes using a variety of DFT functionals, along with two relatively small basis sets, i.e. 176 
LANL2DZ,
40
 and Stuttgart-Dresden ECP/basis set on Pt
41
 with 6-31G(d)
42
 on all other atoms. 177 
DFT methods tested included GGA (BLYP
43
), hybrid (B3LYP,
44
 BHandH
45
), meta-hybrid 178 
(M06-2X
46
) and dispersion corrected (B97-D
47
 and -B97x-D48). However, none of the 179 
methods tested were able to successfully identify any HH1 conformer as the global minimum, 180 
instead typically predicting a HT1 form as having lowest energy. Therefore, we took the 181 
lowest energy structure from each family of conformers, and re-optimised using B97-D with 182 
the def2-TZVP basis set. As shown in Table 1, this larger basis set correctly predicts HH1 as 183 
the global energy minimum of this adduct in PCM calculation of aqueous phase (it should be 184 
noted that NMR experiments used a CD3OD/D2O mixture). HH2 and HT1 forms lie within 185 
ca. 2 kcal/mol, while HT2 is much higher in energy. Optimal geometries four conformers 186 
are shown in Figure 2. 187 
 188 
 189 
Table 1 Relative energy (kcal mol
-1
) and selected geometrical parameters (Å or ˚) calculated 190 
at          B97-D/def2-TZVP level. 191 
 HH1 HH2 HT1 HT2 
Relative E  0.0 +1.37 +2.15 +5.63 
     
Pt-NL 
a 
2.092 2.090 2.089 2.089 
Pt-N7 
a 
2.062 2.056 2.049 2.062 
NL-Pt-NL  98.4 98.7 98.6 97.9 
N7-Pt-N7 90.6 86.5 88.9 89.8 
Dihedral 
b 
83.4 47.4 61.4 59.7 
C8-N7-Pt-NL 
c
 3' 
                       5' 
112.2 
-130.4 
-83.3 
136.5 
-130.3 
-127.7 
128.0 
137.9 
H8...H8 2.214 2.999 3.731 3.342 
NL-HL...O6 3' 
                   5' 
2.380 
1.886 
3.915 
1.858 
1.967 
1.980 
1.941 
1.842 
 192 
a
 Reported as the average of two unique values, that differ by less than 0.002 Å. 
b
 Angle between planes of six 193 
membered rings of the two guanines. 
c
 Torsion angle around Pt-DNA bond, defined relative to C8 in G and N in 194 
1,4-DACH cis to N7.  195 
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 196 
 197 
a)  
 
b) 
 
c) 
 
d) 
 
 198 
Figure 2 DFT optimised structures of 1,4-DACH-GpG adducts in a) HH1, b) HH2, c) HT1 199 
and d)  HT2 conformers. 200 
 201 
Table 1 also contains selected geometrical parameters from these conformations. The 202 
platinum atom is coordinated in a square-planar mode to the cis-1,4-DACH ligand, thus 203 
giving rise to a large bite angle of ca. 98°. The remaining coordination sites are occupied by 204 
two guanine N7 atoms of the oligonucleotides, closing a 17-membered chelate ring. The 205 
greater flexibility of nucleotide coordination is evident in the greater range, almost 4, of 206 
N7—Pt—N7 values observed. Other geometrical aspects of Pt coordination are largely as 207 
 9 
expected, and rather similar to those calculated in similar manner for cisplatin.
26
 For example, 208 
the mean planes of guanines in the HH1 conformer are almost orthogonal at 83°: the 209 
analogous value for HH1 cisplatin-d(GpG) conformer is 86.5°. It is notable, however, that 210 
hydrogen bonds between ligand NH2 groups and base O6 can form despite the bulk of the 211 
1,4-DACH ligand, and that this contact is typically shorter for 5' G than for 3'. This contrasts 212 
with our previous study of kiteplatin bound to double-stranded DNA, for which a strong H-213 
bond to the 3' G was found, but no such interaction for 5' G.
12
 We attribute this difference to 214 
the increased flexibility of the single-stranded oligomer considered here, which allows 215 
guanines to adopt orientations suitable for formation of such H-bonds. However, it is also 216 
apparent that H-bonding is unlikely to be the origin of the stability trend, since both HT 217 
conformers form two N—H…O H-bonds and the shortest such contact of all is found in the 218 
least stable structure. In the 2D-NMR study discussed above, the close contact observed 219 
between H8 nuclei was key to identifying the HH1 conformer: Table 1 shows that only this 220 
form exhibits a close contact between these nuclei. Other interesting information obtained by 221 
the analysis of the optimized HH1 (cis-1,4-DACH)Pt(d(GpG)) adduct (a in Figure 2) are 222 
puckering (N and S for 5'-G and 3'-G, respectively) and conformation (anti for both 5'-G and 223 
3'-G) of the ribose base sugars which correspond to those revealed by the NMR investigation.
 
224 
In addition, both NMR data and computational investigation indicate a left-hand canting 225 
(canting handedness is defined in Scheme 1) of the 5'-G.
17
 226 
 227 
To probe interconversion between isomers in more detail, we carried out relaxed potential 228 
energy scans for rotation about 3´ and 5´ Pt-N7 bonds, starting from the HH1 optimised 229 
geometry. These scans indicate approximate barriers of 10.5 and 18.5 kcal/mol for 3´ and 5´, 230 
respectively; thus we predict that formation of HT1 is kinetically as well as 231 
thermodynamically favoured over HT2. Moreover, Table 1 shows that the HH2 conformer 232 
is slightly lower in energy than the HT1 one, such that one would expect to see more of the 233 
former than the latter if equilibrium between all species were established. However, NMR 234 
experiments show no sign of the HH2 form. We explain this apparent discrepancy by noting 235 
the likely barrier for formation of HH2 from either HT1 or HT2 is likely to involve a 236 
much higher barrier, since it requires the H8 atom of 5' guanine to occupy the same space as 237 
the aromatic rings of 3' guanine, or vice versa and so may not be accessible at experimental 238 
temperatures. Attempts at constructing potential energy scans for this process were 239 
unsuccessful, since the large forces induced gave unrealistic structures for which SCF 240 
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convergence failed. We cannot, therefore, estimate the barrier for formation of HH2 but this 241 
result supports chemical intuition that this conformer may not be accessible at temperatures 242 
used experimentally (0 – 40 C). 243 
 244 
The binding of damage-recognition proteins that control the signal-transduction pathways of 245 
cisplatin and oxaliplatin DNA adducts is highly dependent on the sequence context of the Pt-246 
GG adduct. As an example, the DNA binding protein domain HMGB1a is able to bind to 247 
cisplatin-GG DNA adducts with much greater affinity than to oxaliplatin-GG DNA adducts 248 
in the TGGA sequence context, but presents much smaller differences in binding in the 249 
AGGC or TGGT sequence contexts.
10
 Previous work has shown that the adduct of kiteplatin 250 
with 5'-d(TGGT)-3' results in a single conformer, assigned as having HH orientation of 251 
guanines. Starting from the HH1 structure of the (cis-1,4-DACH)Pt(d(GpG)) conformer, 252 
thymidines in B-DNA geometry were added to each guanine to form a single-stranded TGGT 253 
adduct and optimised at B97-D/6-31+G(d,p)-SDD level. Selected geometrical parameters are 254 
reported in Table 2, and DFT optimised structure is shown in Figure 3. Coordination 255 
geometry is similar to that obtained for the HH1 GpG adduct, as are H8
...
H8 and hydrogen 256 
bond distances: the former is sufficiently short to generate the NOE cross-peaks observed in 257 
the NMR NOESY spectrum.
17
 However, the flanking effect of thymidines leads to a 258 
significant change in the orientation of guanines, which move closer to mutual planarity, with 259 
associated changes in Pt-N7 torsion angles. For this adduct, all attempts to generate 260 
alternative conformers by rotation about Pt—N bonds failed, such that we were only able to 261 
locate the HH1 form, in agreement with the NMR finding of single conformation. 262 
  263 
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Table 2 Selected geometrical parameters for kiteplatin-TGGT adduct (Å or ˚). 264 
Pt-NL 
a 
2.096 
Pt-N7 
a 
2.076 
NL-Pt-NL  97.8 
N7-Pt-N7 86.4 
Dihedral 
b 
65.8 
C8-N7-Pt-NL 3' 
                     5' 
89.4 
-133.1 
H8...H8 2.667 
NL-HL...O6 3' 
                   5' 
3.852 
1.844 
a 
Reported as the average of two unique values. 
b
 Angle between planes of six membered rings of the two 265 
guanines. 
c
 Torsion angle around Pt-DNA bond, defined relative to C8 in G and N in 1,4-DACH cis to N7. 266 
 267 
 268 
Figure 3 B97-D optimised structure of TGGT kiteplatin adduct. Hydrogens have been 269 
omitted for clarity. 270 
 271 
Similarly to the case of HH1 (cis-1,4-DACH)Pt(d(GpG)) adduct, we compared the features of 272 
the optimized HH1 (cis-1,4-DACH)Pt(d(TGGT)) adduct (Figure 3) with data obtained by a 273 
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previous NMR investigation (puckering and conformation of the Gs ribose sugar and canting 274 
of the adduct). Once again, computed data correspond to experimental NMR data as 275 
evidenced by the puckering of the coordinated Gs (N and S for 5'-G and 3'-G, respectively) 276 
and by the conformation (anti for both 5'-G and 3'-G) of the ribose base sugars as well as the 277 
left-hand canting of the 5'-G. 278 
 279 
Adducts with double stranded DNA 280 
Adducts with double-stranded base pair step GG/CC were also constructed from PDB entry 281 
1PGC, and optimisations carried out using B97-D, and optimised structure shown in Figure 4. 282 
Analysis of the resulting structures, as well as those for cisplatin and oxaliplatin adducts 283 
obtained previously,
27
 was performed using X3DNA, with values reported in Table 3. Rise 284 
values show little change for the platinum adducts compared to free DNA, whereas shift and 285 
slide are markedly different to those in free DNA. The largest difference between the B-DNA 286 
and platinum adducts lies in roll values, which increase from 5.4° to approximately 28˚, 287 
with significant changes in twist but little difference in tilt angles. Coordination of the 288 
platinum to the two N7 sites on the adjacent guanines causes the roll angle to increase, 289 
presumably to relieve strain. All three platinum complexes give comparable results: kiteplatin 290 
has slightly smaller rise and less negative slide than the other drugs, but differences between 291 
drugs are rather small compared to the gross difference induced by platination of DNA. 292 
 293 
 294 
Table 3 GG/CC base pair step parameters (Å and ˚). 295 
 Shift Slide Rise Tilt Roll Twist 
Cisplatin -1.39 -1.90 3.51 1.1 28.1 30.4 
Oxaliplatin -1.37 -1.93 3.54 1.0 28.1 31.2 
Kiteplatin -1.39 -1.78 3.46 1.1 27.9 28.7 
B-DNA 
a
 +0.10 +1.41 3.58 -1.1 -5.4 47.9 
a
 Optimised at the same level, starting from canonical geometry. 296 
 297 
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 298 
 299 
Figure 4 B97-D optimised structure of kiteplatin-GG/CC. Sugar phosphate backbone and 300 
CpC shown as wireframe for clarity. 301 
 302 
As well as base-pair geometry, it is instructive to examine the geometry of the sugar 303 
phosphate backbone, as reported in Table 4. Gross differences of up to 40 between 304 
platinated and free DNA are evident in most backbone torsions, along with smaller changes 305 
between drugs. In most cases, cisplatin and oxaliplatin exhibit similar backbone torsions to 306 
one another, while kiteplatin differs from these by around 10. However, there is no clear 307 
pattern on whether the kiteplatin complex is more distorted than the others: some torsion 308 
angles are further from their values in B-DNA, but others are closer than those found for 309 
cisplatin and oxaliplatin complexes.  310 
 311 
 312 
 313 
Table 4 Backbone torsion parameters (˚). 314 
 Cisplatin Oxaliplatin Kiteplatin B-DNA 
a
 
α -75.4 -75.3 -65.5 -36.0 
β -163.3 -163.7 -175.2 130.7 
γ 48.0 47.6 56.6 57.1 
χ b -46.9 -55.4 -32.1 -91.8 
χ c 9.6 -15.4 19.4 -107.1 
δ 127.6 127.2 137.3 140.5 
ε 167.3 -176.5 153.7 -153.2 
ζ -86.2 -86.1 -92.6 -169.9 
a
 Optimised at the same level, starting from canonical geometry; 
b
 For the pentose sugar at the 3’end;  315 
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c
 For the pentose sugar at the 5’ end. 316 
 317 
Binding energies for the three complexes with GG/CC are reported in Table 5. In this data, 318 
oxaliplatin and kiteplatin are closely comparable in that their binding energies differ by less 319 
than 1 kcal/mol irrespective of solvent treatment. These two Pt drugs are isomers of each 320 
other and the binding energies suggest that differences in structure have little significance on 321 
binding. COSMO binding energies show a smaller range than gas phase, with the difference 322 
between weakest and strongest bound changing to 7.6 kcal/mol from 34.1 kcal/mol.  323 
 324 
Table 5 B97-D counterpoise corrected binding energies to GG/CC (kcal/mol). 325 
 Gas Phase Binding Energy COSMO Binding Energy 
Cisplatin -283.9 -129.6 
Oxaliplatin -250.0 -122.6 
Kiteplatin -249.8 -122.0 
 326 
The systems considered so far are the largest that can feasibly be studied using DFT on our 327 
available computing resources. Larger fragments of DNA, as well as explicit consideration of 328 
solvent molecules, require use of multilayer QM/MM techniques. By treating the areas of the 329 
molecule that are of greatest interest, in this case the platinum drug and the directly 330 
coordinated nucleobases, with QM methods and the remainder of the system with MM, 331 
calculations can be carried out on much larger and therefore more realistic biological 332 
systems. The chosen methodology to achieve this has recently been outlined by Gkionis and 333 
Platts,
26
 for optimisation of analogous systems containing cisplatin and explicit water 334 
molecules. It can be difficult to achieve a fully optimised structure, since large molecules 335 
have many degrees of freedom and flat potential energy surfaces. To overcome this, 336 
optimisations were carried out in stages, with parts of the molecule frozen while others were 337 
free to move. By optimising parts at a time the forces for those can be reduced while 338 
maintaining the general structure from the initial construction of the coordinates, allowing 339 
efficient optimisation of complexes containing over one thousand atoms.  340 
 341 
An adduct of kiteplatin with double stranded 5'-d(TG*G*T)-3'5'-d(ACCA)-3', where * 342 
indicates the site of platination, was constructed from PDB entry 1AU5 by truncation of 343 
DNA and manual conversion to 1,4-DACH, retaining the positions of platinum and nitrogen 344 
atoms. Sodium counterions were manually placed in the vicinity of each phosphate group. 345 
 15 
Initial optimisation allowed only the drug and central base pair step to relax, while 346 
coordinates of outer thymines and all backbone atoms were frozen, and proceeded smoothly. 347 
Subsequent optimisation of the entire structure with micro-iterations proved unsuccessful, 348 
resulting in separated DNA strands. Without use of microiterations, the geometry of the 349 
entire adduct could be optimised using the GEDIIS algorithm, leading to the structure shown 350 
in Figure 5. 351 
 352 
 353 
Figure 5 Optimised structure of kiteplatin tetramer, optimised using ONIOM 354 
BHandH/AMBER. MM layer is shown as wireframe for clarity. 355 
 356 
Base pair parameters for this tetramer adduct are reported in Table 6, from which large 357 
deviation of the platinated base pair step from the flanking steps can be observed. This is 358 
most prevalent for the roll parameter, where the platinated bases result in a roll value 359 
significantly greater than for the remaining steps, or indeed the typical value in free DNA 360 
(Table 3). Twist and tilt parameters show large decreases for the central base pair step 361 
compared to the outer steps, whilst shift, slide, and rise are more comparable across the entire 362 
adduct. 363 
  364 
 16 
Table 6 Base pair parameters for kiteplatin duplex-TGGT optimised in the gas phase (Å or ˚). 365 
 Shift Slide Rise Tilt Roll Twist 
TG/CA 0.24 -1.98 2.78 9.9 6.3 30.0 
GG/CC 0.86 -1.33 2.73 -5.5 19.3 22.9 
GT/AC 0.89 -2.50 3.63 7.0 5.6 39.9 
 366 
 367 
The double-stranded octamer of sequence (5'-d(CCTG*G*TCC)-3'5'-d(GGACCAGG)-3') is 368 
of particular interest here, since an NMR structure (PDB entry 1AU5) of its cisplatin complex 369 
has been reported and hence was studied in detail when testing the QM/MM method 370 
employed. The NMR structure of the cisplatin octamer adduct was manually converted into 371 
1,4-DACH, sodium counterions were placed in the vicinity of each phosphate group, and a 372 
water soak was carried out on the system to give a solvation shell of approximately 100 water 373 
molecules, using MOE. Following a similar procedure to that used for the tetramer, the first 374 
step successfully optimised the central base pair step and kiteplatin. Subsequently, the entire 375 
adduct was frozen and only water molecules optimised, then the MM region of DNA was 376 
optimised with central base pair step, kiteplatin, and water frozen. Only once all individual 377 
parts had been separately relaxed was full optimisation attempted. However, even from this 378 
partially relaxed starting point use of micro-iterations was unsuccessful, leading to separated 379 
single strands of DNA. Even without micro-iterations the GEDIIS lead to "unwound" DNA, 380 
such that an intermediate set of optimisation cycles in Cartesian coordinates was deemed 381 
necessary.  382 
 383 
Only after such preliminary optimisation could we reach a fully optimised structure using 384 
microiterations, which is shown in Figure 6, with details in Table 7. Once again, the large 385 
positive roll value and smaller twist angle mark out the platinated central GG/CC step from 386 
those on either side of it. In this larger adduct, however, the rise value of the platinated step is 387 
rather smaller than for the non-platinated ones, and markedly smaller than for any reported 388 
above. The values of rise and roll in Table 7 are also quite different from those found for 389 
cisplatin bound to the same octamer, whether from experiment (5.50 Å and 58.7) or using 390 
analogous QM/MM methods to those employed here (4.97 Å and 48.0), which may give 391 
some insight into the origins of kiteplatin’s different spectrum of activity. 392 
 393 
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 394 
Table 7 Base pair parameters for kiteplatin octamer adduct (Å or ˚). 395 
Step Shift Slide Rise Tilt Roll Twist 
CC/GG -0.55 -0.52 3.03 5.4 -2.3 32.4 
CT/AG 0.66 -0.90 3.76 1.4 -1.1 41.0 
TG/CA -1.33 0.31 2.94 -0.3 -5.2 36.3 
GG/CC 1.10 -0.99 2.80 -3.0 23.6 25.3 
GT/AC 1.03 -1.14 3.71 13.9 5.3 47.2 
TC/GA 0.39 -0.60 3.38 -3.5 7.8 29.8 
CC/GG 0.17 -1.99 3.81 3.5 -7.7 35.7 
 396 
 397 
 398 
 399 
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Figure 6 Optimised structure of kiteplatin octamer; MM layer shown as wireframe.  400 
 401 
An adduct of kiteplatin with dodecameric DNA of sequence (5'-d(CCTCTG*G*TCTCC)-402 
3'5'-d(GGAGACCAGAGG)-3') was constructed from PDB entry 3LPV,14 which contains 403 
oxaliplatin coordinated to the central GG/CC base pair step. The cyclohexane ring was 404 
converted into cis-1,4-DACH by hand and sodium counterions were placed in the vicinity of 405 
every phosphate moiety on the DNA backbone, in place of the mixed sodium and magnesium 406 
atoms present in the PDB structure. To solvate this adduct, a water soak was carried out using 407 
MOE to include approximately 100 explicit water molecules. The same optimisation method 408 
employed above was utilised, initially optimising just the platinum drug and the atoms in the 409 
coordinated base pair step. The explicit water molecules were then optimised with the 410 
remainder of the structure frozen, then MM atoms only optimised with water molecules and 411 
central base pair step frozen. The lowest energy structure was used as the starting point for 412 
full system optimisation in which all atoms are free to move. Once again, preliminary 413 
optimisation in Cartesian coordinates was necessary before full optimisation with GEDIIS 414 
and micro-iterations proved feasible. The optimised structure is shown in Figure 7, and 415 
details of this structure reported in Table 8. As expected, the central, platinated GG/CC step 416 
shows the greatest distortion compared to the remainder of the helix. This is especially 417 
prevalent in the roll parameter, which is significantly larger than reported above for the 418 
shorter DNA sequences. The shift value of the platinated base pair step is also notably larger 419 
than that for the remainder of the DNA helix. 420 
 421 
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 422 
Figure 7 Optimised structure of kiteplatin dodecamer; MM layer shown as wireframe. 423 
 424 
425 
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Table 8 Base pair parameters for kiteplatin dodecamer (Å or ˚). 426 
 Shift Slide Rise Tilt Roll Twist 
CC/GG -0.37 -2.06 3.16 1.2 7.5 26.7 
CT/AG 0.20 -1.71 3.30 1.4 5.2 30.0 
TC/GA 0.09 -1.95 3.28 -2.1 9.9 32.3 
CT/AG -0.14 -2.01 3.14 -0.2 4.8 31.5 
TG/CA -0.38 -1.38 2.92 4.1 8.1 27.1 
GG/CC 1.16 -2.15 3.01 -2.4 34.8 30.2 
GT/AC -0.32 -1.03 3.06 3.1 8.6 33.9 
TC/GA 1.11 -0.30 3.33 3.4 10.5 40.7 
CT/AG -0.31 -0.03 2.91 2.7 13.2 22.7 
TC/GA 0.32 -1.26 4.34 -8.7 11.4 45.3 
CC/GG 0.25 -0.10 2.86 3.1 -5.0 33.0 
 427 
 428 
Comparison of adducts 429 
A comparison of the base pair parameters of the platinated central GG/CC step for each 430 
adduct is shown in Figure 8. It is apparent that, as the size of the DNA fragment increases, 431 
some geometrical values change significantly, most notably in roll and twist which reach 432 
larger values in the larger adducts. The suitability of drawing conclusions from smaller model 433 
systems, such as just the central base pair step, is therefore called into question from this data. 434 
Figure 8 also displays a comparison of base pair step parameters across drugs and for B-DNA 435 
optimised in the same manner. The distortion of DNA caused by drug binding is broadly 436 
similar for each drug, with platination inducing positive shift, negative slide and much larger 437 
roll values in all cases. However, there are subtle differences between the drugs considered: 438 
in all values reported, kiteplatin is actually more similar to cisplatin, while oxaliplatin appears 439 
as the “odd one out” in this data.  440 
 441 
442 
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Table 9 Geometrical parameters for kiteplatin-adduct with double stranded DNA (Å or ˚). 443 
 Dimer Tetramer Octamer Dodecamer 
Pt-NL 
a 
2.040 2.037 2.041 2.029 
Pt-N7 
a 
2.029 2.030 2.020 2.042 
NL-Pt-NL  99.2 99.8 96.4 96.6 
N7-Pt-N7 84.2 86.1 84.4 86.5 
C8-N7-Pt-NL 3' 
                     5'  
+140.1 
-96.7 
+125.1 
-101.8 
+113.3 
-84.0 
+135.5 
-80.8 
H8...H8 2.944 3.417 3.418 3.323 
NL-HL...O6  3' 
                   5' 
1.720 
3.361 
1.742 
3.213 
2.824 
3.878 
1.766 
3.808 
a
 Reported as the average of two unique values. 
b
 Torsion angle around Pt-DNA bond, defined relative to C8 in 444 
G and N in 1,4-DACH cis to N7.  445 
 446 
 447 
Table 9 reports selected geometrical parameters regarding the coordination of kiteplatin to 448 
DNA fragments of different length. These data suggest that the adduct size has a negligible 449 
effect on the Pt-N bond lengths for both ligand and guanine base, while the longer adducts 450 
(octamer and dodecamer) exhibit a tightening of the angle NL-Pt-NL. For the N7-Pt-N7 angle, 451 
and the C8-N7-Pt-NL torsions, the calculated values do not suggest any specific tendency. As 452 
expected, the H8...H8 distance is closer in the dimer, where the two guanines have no 453 
flanking bases enforcing stacking, while the distances stay reasonably similar for the 454 
tetramer, octamer, and dodecamer, reinforcing the idea that the addition of just two base pairs 455 
(3’ and 5’) is sufficient to restrict the mobility of the platinated guanines similarly to longer 456 
sequences. The hydrogen bonding distances HL...O6 are remarkably similar for the 3’G, with 457 
the exception of the octamer, around 1.7 Angstrom. The corresponding distance in 5’G, are 458 
very similar (about 3.3 Å) for the dimer and tetramer, while in the case of the octamer and 459 
dodecamer they are longer, around 3.8 Å, in both situations out of the acceptable range for 460 
hydrogen bonding.
49
 461 
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Figure 8 Geometry of platinated base-pair steps in different adducts: top row, kiteplatin bound to different DNA fragments; bottom: different drugs bound to 
octameric DNA: Cis = cisplatin, Ox = oxaliplatin, Kite = kiteplatin (Å or ˚).  
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Table 10 reports binding energies of kiteplatin to different DNA sequences, evaluated both in gas phase 
and simulated aqueous solvent. To calculate these values, explicit water molecules were removed from 
the systems, where present, and three single point energy calculations were carried out, on the platinum 
complex, the remainder of the DNA plus sodium counterions, and on the entire adduct. An implicit 
solvent model was chosen, instead of the already present explicit solvent molecules, to avoid the issue of 
assigning the water molecules in close proximity to the platinum to one of the two fragments. Gas phase 
values indicate that kiteplatin binds most weakly to the dimer, with a large increase to the tetramer and 
smaller increases for the octamer and dodecamer respectively. Aqueous phase data show a similar pattern, 
where the dimer is the weakest and binding becomes stronger as the size of the DNA adducts increase. In 
both cases, the dodecamer actually has slightly weaker binding than the octamer, but overall both series 
of values appear to converge as more bases are added. Kiteplatin’s binding energy to octameric DNA lies 
between that reported previously for cisplatin (-245.4 kcal/mol in PCM water) and oxaliplatin (-299.6 
kcal/mol), indicating that isomerisation of the DACH from 1,2 to 1,4 adversely affects binding somewhat, 
but that both isomers are more strongly bound than cisplatin.  
 
Table 10 ONIOM binding energies of kiteplatin to DNA Adducts (kcal/mol). 
 Gas Phase PCM Aqueous 
Dimer -271.6 -33.8 
Tetramer -429.8 -186.0 
Octamer -473.5 -282.4 
Dodecamer -445.5 -277.2 
 
 
The exposed surface areas of drug in complex with DNA are reported in Table 11. The dimer has the 
largest exposed area, presumably due to having the smallest DNA fragment, and as the DNA chain is 
extended the drug becomes more buried. The octamer has the lowest exposed area, whilst the dodecamer 
has a slightly higher value, similar to the pattern observed in binding energies. Once again, values 
apparently converge as the size of the DNA helix increases, which is what would be expected as the 
greater size of the DNA reduces the exposed surface of the drug. Comparisons to known drugs bound to 
octameric DNA show that kiteplatin is much more exposed to its environment than both cisplatin (63.2 
Å
2
) and slightly more so than oxaliplatin (117.1 Å
2
). The data describing the environment of the platinum 
centre (Table 9), overall agree with the data regarding the binding energies (Table 10, PCM) and the 
exposed surface area (Table 11). The values for the dimer and tetramer are quite different, while much 
closer for the octamer and dodecamer, with the binding energy increasing with the decreasing exposed 
 24 
area. Interestingly, the octamer has a lower PCM binding energy, and a lower exposed area than the 
dodecamer, which may give some insight into why the former is more strongly bound. 
 
Table 11 Exposed surface area of kiteplatin in DNA complexes (Å
2
). 
 Exposed Area 
Dimer 164.2 
Tetramer 135.1 
Octamer 120.7 
Dodecamer 124.1 
 
 
Conclusions 
We have used theoretical calculations to probe the binding of kiteplatin to DNA, that, in some cases, had 
already been investigated by NMR experiments. Concerning single-stranded DNA oligomers, the 
dynamic behaviour of kiteplatin bound d(GpG), as revealed by NMR spectroscopy, is quite different from 
the one observed for cisplatin  and its closest isomer currently used in therapy, oxaliplatin. The addition 
of bases to the model to form d(TGGT) globally slows the dynamic motion, showing a single conformer 
at room temperature. DFT calculations for the d(GpG) and d(TGGT) show that the main binding features 
at the platinum centre remain very similar (bonding distances, angles), with the only significant exception 
of the rotation of guanines around N7-Pt bond, a variation that can be attributed to the additional  base-
base interactions in the expanded sequence. As far as the structural features of the d(GpG)- and d(TGGT)-
kiteplatin adducts concerns (puckering and conformation of the coordinated Gs ribose sugar and canting 
of the adduct), theoretical data confirm the NMR characterization previously performed on these 
compounds. 
 
Adducts of kiteplatin with double-stranded DNA consisting of between 2 and 12 base pairs have also 
been examined theoretically, the larger cases requiring use of multilayer QM/MM methods that treat 
kiteplatin plus coordinate guanines with DFT and the remainder of the system with an atomistic 
forcefield. This approach allows us to calculate geometrical details associated with both coordination of 
Pt to guanine and the overall structure of DNA that results, as well as binding energy and exposed surface 
area of drug, comparing key quantities against other drugs. This analysis indicates that kiteplatin behaves 
more like cisplatin than oxaliplatin, despite being an isomer of the latter. However, kiteplatin and 
cisplatin DNA adducts differ markedly for the exposed surface area of the two drugs which is almost 
twofold higher in the case of kiteplatin. Since the bulk and shape of the carrier ligand in a Pt-based 
complex, as it projects out away from the DNA helix, will influence its interactions with nucleic acid 
 25 
binding proteins or repair enzymes, we hypothesise that this peculiar feature of kiteplatin-DNA adducts 
could influence the markedly different pharmacological activity of this drug. 
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